- Active not recruitingPHASE1
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
This study looks at a new combination of two medicines, Ceralasertib and Acalabrutinib, for people in the UK with a specific type of blood cancer called Chronic Lymphocytic Leukaemia (CLL). It wants to find out if this combination is safe and how well it works when other treatments haven't helped.
For: Chronic Lymphocytic LeukemiaPoland · United Kingdom - Active not recruitingPHASE3
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
This study looks at a new combination of drugs, ceralasertib and durvalumab, for people with advanced lung cancer that has grown after previous treatments. It compares this new combination to a standard chemotherapy drug, docetaxel, to see which works better and is safer.
For: Advanced or Metastatic Non-Small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE1
A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
This study looks at combining radiotherapy with new drugs to treat non-small cell lung cancer that hasn't spread widely. Researchers want to find the safest and most effective dose of these new drugs, which help radiotherapy work better by making it harder for cancer cells to repair themselves.
For: Non Small Cell Lung CancerUnited Kingdom - Active not recruitingPHASE2
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
This study looks at new treatments (Ceralasertib alone or with Durvalumab) for people with advanced melanoma that has stopped responding to standard immunotherapy. It aims to see how well they work and if they are safe.
For: MelanomaUnited States · Australia · Belgium - RecruitingPHASE1, PHASE2
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
This study is for children and young people with cancer that hasn't responded to usual treatments. It tests new medicines that target specific changes in cancer cells, aiming to find the right dose and see if they help. The goal is to find better ways to treat childhood cancer.
For: Pediatric CancerDenmark · France · Italy - Active not recruitingPHASE2
ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss
This study looks at new treatments for gynaecological cancers that have come back. It tests a drug called ceralasertib, sometimes with olaparib or durvalumab, to see how well they work in different types of cancer cells, especially those with a specific gene change called ARID1A loss.
For: Gynaecological CancersCanada · United Kingdom